Health
AIDS Activists Criticize R&D Deal
AIDS activists have criticized a research and development (R&D) deal between the U.S. government and Gilead Sciences over patents for HIV prevention drugs.
Coverage timeline — 1 article
STAT News
A group of AIDS activists obtained an R&D pact at the heart of a settlement between the U.S. government and Gilead Sciences over patents for HIV prevention.
2026-07-13 20:58 UTC